Current Status of Oral Carbapenem Development

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)


Volume 14, 2 Issues, 2016


Download PDF Flyer




Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Current Status of Oral Carbapenem Development



Anti-Infective Agents, 1(1): 1-14.

Author(s): Toshio Kumagai, Satoshi Tamai, Takao Abe and Muneo Hikda.

Affiliation: Medical Research Laboratories, Wyeth Lederle (Japan) Ltd., 1-6-34, Kashiwa-cho, Shiki-shi, Saitama 353-8511, Japan

Abstract

Since the discovery of thienamycin (1) in 1976, many studies on the synthesis and structure-activity relationships of parenteral-use drugs have been done and several carbapenems, imipenem (2), panipenem (3), and meropenem (7), have been marketed. The development of oral carbapenems, however, is a fairly slow process because carbapenems are considered unstable in the stomach and intestine. Recently, several orally active carbapenems without stability problems have been developed as prodrug esters or prodrug peptides, including GV-118819 (12), CS-834 (13), L-084 (14), DZ-2640 (15), and peptidic derivatives of CL 191,121 (16). The active forms (35), (41), (44), (45), (16) of these prodrugs exhibited potent and well balanced antibacterial activities as well as resistance to renal dehydropeptidase-I. The pharmacokinetic parameters of compounds (12), (13), (14), and (15) after oral administration to healthy volunteers were reported. The half-life (t1 / 2) of GV-118819 (12) was longer than that of the other compounds, while the Cmax, AUC and urinary excretion rate of L-084 (14) were higher than those of the others. In this review, the synthesis, chemical and biological properties, and pharmacokinetics of these oral carbapenems are described.

Keywords:

Carbapenem Development, Thienamycin, Imipenem, Panipenem, Meropenem, Synthsis, Beta-Methlazetidin-2-one.



Download Free Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 1
Issue Number: 1
First Page: 1
Last Page: 14
Page Count: 14
DOI: 10.2174/1568012023355018
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science